glp 1/gip agonist Main physiological actions of the dual GIP and GLP-1 Polyagonists Enable Increasingly Effective Treatment
Description
Saxendas approval set a precedent in efficacy and pricing, with a cost of over $1,000 per month
In addition, many of these patients will have additional risk factors for delayed gastric emptying (for example, diabetes or obesity) which must be taken into consideration
Stopping these drugs without a clear reason may work against those benefits
& Tan, T
( Epub 20220105 )
